Table 3. Association of two independent SNPs on 8q24.22 in different phenotypes.
| SNP | rs2294025 | rs7005834 | |||||
|---|---|---|---|---|---|---|---|
| RAF (%) | P | OR (95% CI) | RAF (%) | P | OR (95% CI) | ||
| Female GD vs. female Control | 22/20 | 2.77E-07 | 1.16 (1.10–1.23) | 15/16 | 6.38E-05 | 1.14 (1.07–1.22) | |
| Male GD vs. male Control | 21/19 | 0.0075 | 1.15 (1.04–1.28) | 13/16 | 0.0006 | 1.23 (1.1–1.39) | |
| Female GD vs. male GD | 22/21 | 0.2929 | 1.05 (0.96–1.14) | 15/13 | 0.0619 | 0.91 (0.82–1.00) | |
| pTRAb+ vs. pTRAb− | 23/23 | 0.9568 | 1.00 (0.88–1.15) | 15/14 | 0.3823 | 0.93 (0.80–1.09) | |
| GO vs. nonGO | 22/21 | 0.6475 | 1.03 (0.92–1.14) | 14/15 | 0.3627 | 1.06 (0.94–1.20) | |
| TGAb+ vs. TGAb− | 26/22 | 0.1145 | 1.22 (0.95–1.55) | 16/14 | 0.2372 | 0.84 (0.63–1.12) | |
| TPOAb+ vs. TPOAb− | 23/23 | 0.6829 | 0.96 (0.80–1.16) | 14/15 | 0.4787 | 1.08 (0.87–1.34) | |
SNP, single nucleotide polymorphism; RAF, risk allele frequency; OR, odds ratio; CI, confidence interval; GD, Graves’ disease; pTRAb+, persistent TRAb positivity; GO, Graves’ ophthalmopathy.